GeneOne Life Science, Inc. (011000.KS)
KRW 2035.0
(-3.1%)
KRW 2035.0
(-3.1%)
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2023 | -14.98 Billion KRW | -260.5% |
| 2022 | 9.33 Billion KRW | 6.6% |
| 2021 | 8.75 Billion KRW | -23.26% |
| 2020 | 11.41 Billion KRW | -11.46% |
| 2019 | 12.88 Billion KRW | 20.49% |
| 2018 | 10.69 Billion KRW | 89.14% |
| 2017 | 5.65 Billion KRW | -30.15% |
| 2016 | 8.09 Billion KRW | 5.94% |
| 2015 | 7.64 Billion KRW | 91.07% |
| 2014 | 4 Billion KRW | -4.17% |
| 2013 | 4.17 Billion KRW | 112.18% |
| 2012 | 1.96 Billion KRW | -55.72% |
| 2011 | 4.44 Billion KRW | -24.24% |
| 2010 | 5.86 Billion KRW | 683.14% |
| 2009 | 748.82 Million KRW | -40.94% |
| 2008 | 1.26 Billion KRW | -7.16% |
| 2007 | 1.36 Billion KRW | 0.0% |
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2024 Q1 | -4.01 Billion KRW | -45.24% |
| 2024 Q2 | -3.78 Billion KRW | 5.58% |
| 2023 FY | -14.98 Billion KRW | -260.5% |
| 2023 Q1 | -1.57 Billion KRW | 34.71% |
| 2023 Q2 | -3.9 Billion KRW | -148.63% |
| 2023 Q3 | -1.27 Billion KRW | 67.39% |
| 2023 Q4 | -2.76 Billion KRW | -116.83% |
| 2022 Q2 | 6.2 Billion KRW | 75.85% |
| 2022 Q3 | 2 Billion KRW | -67.7% |
| 2022 FY | 9.33 Billion KRW | 6.6% |
| 2022 Q4 | -2.4 Billion KRW | -220.07% |
| 2022 Q1 | 3.53 Billion KRW | 178.49% |
| 2021 Q1 | 2.17 Billion KRW | -21.68% |
| 2021 FY | 8.75 Billion KRW | -23.26% |
| 2021 Q4 | 1.26 Billion KRW | 96.23% |
| 2021 Q2 | 4.67 Billion KRW | 115.04% |
| 2021 Q3 | 645.98 Million KRW | -86.17% |
| 2020 Q4 | 2.77 Billion KRW | -4.42% |
| 2020 FY | 11.41 Billion KRW | -11.46% |
| 2020 Q3 | 2.9 Billion KRW | -19.26% |
| 2020 Q2 | 3.59 Billion KRW | 67.81% |
| 2020 Q1 | 2.14 Billion KRW | -46.07% |
| 2019 FY | 12.88 Billion KRW | 20.49% |
| 2019 Q1 | 2 Billion KRW | -38.7% |
| 2019 Q2 | 3.03 Billion KRW | 50.88% |
| 2019 Q3 | 3.87 Billion KRW | 27.92% |
| 2019 Q4 | 3.97 Billion KRW | 2.42% |
| 2018 Q3 | 2.8 Billion KRW | 18.52% |
| 2018 Q4 | 3.27 Billion KRW | 16.75% |
| 2018 Q2 | 2.36 Billion KRW | 5.53% |
| 2018 Q1 | 2.24 Billion KRW | 126.22% |
| 2018 FY | 10.69 Billion KRW | 89.14% |
| 2017 Q1 | 1.76 Billion KRW | -42.99% |
| 2017 Q3 | 1.7 Billion KRW | 42.54% |
| 2017 Q4 | 992.12 Million KRW | -41.85% |
| 2017 FY | 5.65 Billion KRW | -30.15% |
| 2017 Q2 | 1.19 Billion KRW | -32.02% |
| 2016 Q4 | 3.08 Billion KRW | 93.46% |
| 2016 FY | 8.09 Billion KRW | 5.94% |
| 2016 Q3 | 1.59 Billion KRW | -11.89% |
| 2016 Q2 | 1.81 Billion KRW | 13.19% |
| 2016 Q1 | 1.6 Billion KRW | 8.87% |
| 2015 Q1 | 1.47 Billion KRW | 250.81% |
| 2015 Q3 | 2.28 Billion KRW | -5.34% |
| 2015 FY | 7.64 Billion KRW | 91.07% |
| 2015 Q4 | 1.47 Billion KRW | -35.6% |
| 2015 Q2 | 2.41 Billion KRW | 63.19% |
| 2014 Q4 | -980.08 Million KRW | -179.51% |
| 2014 FY | 4 Billion KRW | -4.17% |
| 2014 Q3 | 1.23 Billion KRW | -20.55% |
| 2014 Q2 | 1.55 Billion KRW | -29.37% |
| 2014 Q1 | 2.19 Billion KRW | -39.16% |
| 2013 Q2 | -189.9 Million KRW | -195.04% |
| 2013 Q1 | 199.81 Million KRW | -76.69% |
| 2013 Q3 | 554.22 Million KRW | 391.84% |
| 2013 Q4 | 3.61 Billion KRW | 551.39% |
| 2013 FY | 4.17 Billion KRW | 112.18% |
| 2012 FY | 1.96 Billion KRW | -55.72% |
| 2012 Q2 | 168.91 Million KRW | -39.79% |
| 2012 Q3 | 1.02 Billion KRW | 506.97% |
| 2012 Q4 | 857.25 Million KRW | -16.39% |
| 2012 Q1 | 280.54 Million KRW | 0.0% |
| 2011 Q3 | 337.63 Million KRW | -33.39% |
| 2011 FY | 4.44 Billion KRW | -24.24% |
| 2011 Q2 | 506.91 Million KRW | -25.84% |
| 2011 Q1 | 683.5 Million KRW | 0.0% |
| 2011 Q4 | - KRW | -100.0% |
| 2010 FY | 5.86 Billion KRW | 683.14% |
| 2010 Q3 | 442.62 Million KRW | 10.77% |
| 2010 Q2 | 399.59 Million KRW | 146.03% |
| 2010 Q1 | 162.41 Million KRW | 0.0% |
| 2010 Q4 | - KRW | -100.0% |
| 2009 Q2 | 14.93 Million KRW | -95.88% |
| 2009 Q3 | 108.43 Million KRW | 626.28% |
| 2009 Q4 | - KRW | -100.0% |
| 2009 FY | 748.82 Million KRW | -40.94% |
| 2009 Q1 | 361.94 Million KRW | 5.22% |
| 2008 Q3 | 271.98 Million KRW | -22.48% |
| 2008 Q4 | 343.99 Million KRW | 26.47% |
| 2008 FY | 1.26 Billion KRW | -7.16% |
| 2008 Q2 | 350.85 Million KRW | 16.56% |
| 2008 Q1 | 301 Million KRW | -21.15% |
| 2007 Q4 | 381.74 Million KRW | 7.56% |
| 2007 Q2 | 271.9 Million KRW | -23.84% |
| 2007 Q3 | 354.9 Million KRW | 30.52% |
| 2007 Q1 | 357.01 Million KRW | 0.0% |
| 2007 FY | 1.36 Billion KRW | 0.0% |
| Name | Gross Profit | Gross Profit Difference |
|---|---|---|
| ORIENT BIO Inc. | 9.58 Billion KRW | 256.341% |
| Green Cross Holdings Corporation | 603.58 Billion KRW | 102.483% |
| Green Cross Holdings Corporation | 458.68 Billion KRW | 103.267% |
| Pharmicell Co., Ltd. | 14.95 Billion KRW | 200.195% |
| Green Cross Corporation | 458.68 Billion KRW | 103.267% |
| Celltrion, Inc. | 1010.9 Billion KRW | 101.482% |
| Samsung Biologics Co.,Ltd. | 1802.76 Billion KRW | 100.831% |
| SK bioscience Co.,Ltd. | 142.24 Billion KRW | 110.534% |
| SK Biopharmaceuticals Co., Ltd. | 308.37 Billion KRW | 104.859% |
| Prestige BioPharma Limited | 689.07 Million KRW | 2274.554% |